Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
AstraZeneca
Medtronic
Moodys

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,046,000

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,046,000
Title:Use of 2-methylene-19-nor-(20S)-1.alpha.,25-Dihydroxyvitamin D.sub.3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure
Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
Inventor(s): DeLuca; Hector F. (Deerfield, WI), Plum; Lori A. (Arena, WI), Zella; Julia B. (Horicon, WI), Clagett-Dame; Margaret (Deerfield, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:15/604,069
Patent Claims:1. A method for prophylactic treatment of a symptom of secondary hyperparathyroidism (SHPT) comprising administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 (2MD) or a pharmaceutically acceptable salt thereof to a subject having renal failure; wherein the symptom of secondary hyperparathyroidism (SHPT) is selected from the group consisting of elevated serum PTH, elevated serum phosphorus, and elevated serum creatine and the method does not induce hypercalcemia in the subject.

2. The method of claim 1, wherein the therapeutically effective amount ranges from about 1 ng/kg bw to about 10 ng/kg bw.

3. The method of claim 1, wherein the subject is administered a therapeutically effective amount of 2MD three times per week.

4. The method of claim 1, wherein the subject has SHPT, and the 2MD is administered at a therapeutically effective amount for treating the SHPT or symptoms thereof without inducing hypercalcemia in the subject.

5. The method of claim 4, wherein the treated symptoms of SHPT are selected from the group consisting of elevated serum parathyroid hormone (PTH), elevated serum phosphorus, and elevated serum creatinine.

6. The method of claim 1, wherein the 2MD is formulated in an oral, topical, transdermal, parenteral, injection or infusion dosage form.

7. A method for prophylactic treatment of a symptom of secondary hyperparathyroidism (SHPT) comprising administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 (2MD) or a pharmaceutically acceptable salt thereof to a subject having a renal glomerular filtration rate of less than 15 mL/min/1.73 m.sup.2; wherein the symptom of secondary hyperparathyroidism (SHPT) is selected from the group consisting of elevated serum PTH, elevated serum phosphorus, and elevated serum creatine and the method does not induce hypercalcemia in the subject.

8. The method of claim 7, wherein the therapeutically effective amount ranges from about 1 ng/kg bw to about 10 ng/kg bw.

9. The method of claim 7, wherein the subject is administered a therapeutically effective amount of 2MD three times per week.

10. The method of claim 7, wherein the subject has SHPT, and the 2MD is administered at a therapeutically effective amount for treating the SHPT or symptoms thereof without inducing hypercalcemia in the subject.

11. The method of claim 10, wherein the treated symptoms of SHPT are selected from the group consisting of elevated serum parathyroid hormone (PTH), elevated serum phosphorus, and elevated serum creatinine.

12. The method of claim 7, wherein the 2MD is formulated in an oral, topical, transdermal, parenteral, injection or infusion dosage form.

13. A method for prophylactic treatment of a symptom of secondary hyperparathyroidism (SHPT) comprising administering 2-methylene-19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3 (2MD) or a pharmaceutically acceptable salt thereof to a subject receiving hemodialysis treatment; wherein the symptom of secondary hyperparathyroidism (SHPT) is selected from the group consisting of elevated serum PTH, elevated serum phosphorus, and elevated serum creatine and the method does not induce hypercalcemia in the subject.

14. The method of claim 13, wherein the therapeutically effective amount ranges from about 1 ng/kg bw to about 10 ng/kg bw.

15. The method of claim 13, wherein the subject is administered a therapeutically effective amount of 2MD three times per week.

16. The method of claim 13, wherein the subject has SHPT, and the 2MD is administered at a therapeutically effective amount for treating the SHPT or symptoms thereof without inducing hypercalcemia in the subject.

17. The method of claim 16, wherein the treated symptoms of SHPT are selected from the group consisting of elevated serum parathyroid hormone (PTH), elevated serum phosphorus, and elevated serum creatinine.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
AstraZeneca
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.